Zenyaku Kogyo
As of the edition of 20 October 2026, Zenyaku Kogyo runs 2 drugs, 1 of them marketed; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Rituximab | Ends 2028 (orphan exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
| Target | Route |
|---|---|
| PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Route A |
| PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Route A |
| PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Route A |
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Zenyaku Kogyo needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 2 trials led